Immunic, Inc. Outlines Upcoming Conferences for November 2025

Author: Dylan Bailey Updated: 10-29-2025 06:40 AM

Immunic, Inc. Announces Conference Participation for November

NEW YORK — Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in key industry and investor conferences this coming November.

Details of Upcoming Conferences

Immunic is set to join various industry forums including:

BIO-Europe Conference

From November 3-5, key members of the Immunic team, including CEO Daniel Vitt, Ph.D., Chief Scientific Officer Hella Kohlhof, Ph.D., and Vice President of Investor Relations and Communications Jessica Breu, will engage in partnering activities at the BIO-Europe Conference held in Vienna, Austria. Interested parties can utilize the official partnering system to schedule meetings.

Jefferies Global Healthcare Conference

Additionally, Dr. Vitt, alongside Jason Tardio, President and COO of Immunic, will host one-on-one meetings in London on November 19-20. This event is in conjunction with the Jefferies Global Healthcare Conference - London. Stakeholders should reach out to Jessica Breu to arrange discussions during this opportunity.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) specializes in small molecule therapies aimed at treating chronic inflammatory and autoimmune conditions. Their lead candidate, vidofludimus calcium (IMU-838), is undergoing phase 3 trials targeting relapsing multiple sclerosis, showcasing promising therapeutic activity based on prior phase 2 results. This innovative therapy works on neuroprotection while also addressing inflammation.

Moreover, Immunic is developing IMU-856 to enhance intestinal barrier function, which may benefit various gastrointestinal disorders. Their commitment also includes developing IMU-381, currently in preclinical stages, designed to meet the needs of patients with gastrointestinal issues.

Further Information

For more information about Immunic's initiatives and upcoming presentations, please visit their official website. The firm continues to advance its projects and engage with the healthcare investor community to share its vision and developments.

Frequently Asked Questions

What is the focus of Immunic, Inc.?

Immunic, Inc. is focused on developing small molecule therapies for chronic inflammatory and autoimmune diseases.

What major conferences will Immunic participate in this November?

The company will be attending the BIO-Europe Conference from November 3-5 and the Jefferies Global Healthcare Conference on November 19-20.

Who are the key personnel attending these events?

Key personnel include CEO Daniel Vitt and President and COO Jason Tardio, along with Jessica Breu, the Vice President of Investor Relations.

What is vidofludimus calcium?

Vidofludimus calcium (IMU-838) is Immunic's lead therapeutic candidate, currently in phase 3 clinical trials for treating relapsing multiple sclerosis.

How can I schedule a meeting with Immunic's representatives?

Interested individuals should contact Jessica Breu or utilize the digital partnering platform for the conferences.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.